Drug Profile
Research programme: stem cell therapies - VIRxSYS
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator VIRxSYS Corporation
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)